4.7 Article

Daptomycin Activity against Uncommonly Isolated Streptococcal and Other Gram-Positive Species Groups

Journal

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 57, Issue 12, Pages 6378-6380

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01906-13

Keywords

-

Funding

  1. Cubist Pharmaceuticals
  2. Achaogen
  3. Aires
  4. American Proficiency Institute (API)
  5. Anacor
  6. Astellas
  7. AstraZeneca
  8. bioMerieux
  9. Cempra
  10. Cerexa
  11. Contrafect
  12. Cubist
  13. Dipexium
  14. Enanta
  15. Furiex
  16. GlaxoSmithKline
  17. Johnson Johnson
  18. LegoChem Biosciences Inc.
  19. Meiji Seika Kaisha
  20. Nabriva
  21. Novartis
  22. Pfizer
  23. PPD Therapeutics
  24. Premier Research Group
  25. Rempex
  26. Rib-X Pharmaceuticals
  27. Seachaid
  28. Shionogi
  29. Medicines Co.
  30. Theravance
  31. Thermo Fisher

Ask authors/readers for more resources

A total of 1,356 clinical isolates were tested against daptomycin by broth microdilution methods. Daptomycin was active against seven groups of viridans group streptococci (MIC50 and MIC90 values ranging from <= 0.06 and <= 0.06 mu g/ml [Streptococcus bovis and Streptococcus dysgalactiae] to 0.5 and 1 mu g/ml [Streptococcus mitis, Streptococcus oralis, and Streptococcus parasanguinis], respectively), beta-hemolytic streptococci serogroups C, F, and G (MIC50 and MIC90, <= 0.06 to 0.25 and 0.12 to 0.25 mu g/ml, respectively), Corynebacterium spp. (MIC50 and MIC90, <= 0.06 and 0.12 mu g/ml, respectively), and Micrococcus spp. (MIC50 and MIC90, <= 0.06 and 0.25 mu g/ml, respectively). Listeria monocytogenes exhibited higher daptomycin MICs (MIC50 and MIC90, 2 and 4 mu g/ml, respectively) than other tested organisms.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Microbiology

Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010-2019)

Cecilia G. Carvalhaes, Helio S. Sader, Jennifer M. Streit, Mariana Castanheira, Rodrigo E. Mendes

Summary: According to data from a 10-year study, oritavancin has shown strong activity against Gram-positive pathogens that cause bloodstream infections, and has demonstrated good efficacy against resistant strains of MRSA and Enterococcus.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

Article Infectious Diseases

Antimicrobial activities of aztreonam-avibactam and comparator agents tested against Enterobacterales from European hospitals analysed by geographic region and infection type (2019-2020)

Helio S. Sader, Rodrigo E. Mendes, S. J. Ryan Arends, Cecilia G. Carvalhaes, Mariana Castanheira

Summary: The study evaluated the activity of aztreonam-avibactam against Enterobacterales isolates from European medical centers and the occurrence of carbapenemases. The results showed that aztreonam-avibactam had high inhibitory activity against Enterobacterales isolates and retained potent activity against resistant strains. The study also found that isolates from the Eastern European and Mediterranean region had lower susceptibility to comparator agents compared to isolates from Western Europe.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2022)

Article Infectious Diseases

Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018-19)

Helio S. Sader, Rodrigo E. Mendes, Leonard R. Duncan, Cecilia G. Carvalhaes, Mariana Castanheria

Summary: The study evaluated the activity of cefepime/zidebactam against Gram-negative bacteria, showing good efficacy against Enterobacterales and carbapenem-resistant isolates. It demonstrated potential antibiotic effects on a global scale.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)

Article Immunology

Activity of Tedizolid and Comparator Agents Against Gram-positive Isolates Causing Skin and Skin Structure Infections in Pediatric Patients in United States Hospitals (2015-2019)

Cecilia Godoy Carvalhaes, Helio Silva Sader, Paul Richard Rhomberg, Mariana Castanheira, Sean DeVries, Rodrigo Elisandro Mendes

Summary: This study assessed the activity of tedizolid and comparator agents against clinical surveillance isolates collected from pediatric patients with skin and skin structure infection in the United States. The results showed that tedizolid had high inhibitory activity against Staphylococcus aureus and MRSA isolates, and other antibiotics also displayed high susceptibility in different age groups and methicillin resistance profiles.

PEDIATRIC INFECTIOUS DISEASE JOURNAL (2022)

Article Infectious Diseases

Update on the in vitro activity of ceftaroline against Staphylococcus aureus from United States (US) medical centers stratified by infection type (2018-2020)

Helio S. Sader, Mariana Castanheira, Leonard R. Duncan, Rodrigo E. Mendes

Summary: Ceftaroline showed high susceptibility against different types of infections, and it also exhibited good activity against methicillin-resistant strains.

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2023)

Article Infectious Diseases

Comparative activity of newer ?-lactam/?-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021)

Helio S. Sader, Rodrigo E. Mendes, S. J. Ryan Arends, Cecilia G. Carvalhaes, Dee Shortridge, Mariana Castanheira

Summary: This study evaluated the in-vitro activity of several antibiotics against contemporary Pseudomonas aeruginosa isolates and found that ceftazidime-avibactam, ceftolozane-tazobactam, and imipenem-relebactam showed excellent activity against multi-drug resistant strains.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2023)

Article Immunology

Impact of the Recent Clinical and Laboratory Standards Institute Breakpoint Changes on the Antimicrobial Spectrum of Aminoglycosides and the Activity of Plazomicin Against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales From United States Medical Centers

Helio S. Sader, Rodrigo E. Mendes, John H. Kimbrough, Valerie Kantro, Mariana Castanheira

Summary: The CLSI lowered the breakpoints for amikacin, gentamicin, and tobramycin, which are commonly used to treat multidrug-resistant Enterobacterales infections. These changes resulted in a reduction in the susceptibility rates of Enterobacterales, particularly against resistant subsets. Plazomicin demonstrated potent activity against antimicrobial-resistant Enterobacterales, including CRE and MDR strains.

OPEN FORUM INFECTIOUS DISEASES (2023)

Article Immunology

Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019-2021)

Helio S. Sader, Rodrigo E. Mendes, Cecilia G. Carvalhaes, John H. Kimbrough, Mariana Castanheira

Summary: As the prevalence of metallo-beta-lactamase (MBL)-producing Enterobacterales is increasing, there is an urgent need for effective antimicrobials. This study evaluated the activity of aztreonam-avibactam against 27,834 Enterobacterales isolates collected from US medical centers. The results showed that aztreonam-avibactam was highly effective, inhibiting over 99.9% of isolates at a concentration of <= 8 mg/L.

OPEN FORUM INFECTIOUS DISEASES (2023)

Article Microbiology

Development of Modernized Acinetobacter baumannii Susceptibility Test Interpretive Criteria for Recommended Antimicrobial Agents Using Pharmacometric Approaches

A. J. Lepak, M. Trang, J. P. Hammel, H. S. Sader, S. M. Bhavnani, B. D. VanScoy, J. M. Pogue, P. G. Ambrose, D. R. Andes

Summary: STIC using only epidemiological data may not accurately reflect the therapeutic effect of antimicrobial agents against A. baumannii. In this study, a comprehensive evaluation was conducted using in vitro surveillance data, preclinical murine models, and population pharmacokinetics to establish appropriate STIC for commonly recommended antimicrobials.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2023)

Article Infectious Diseases

Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018-2022)

Helio S. Sader, Rodrigo E. Mendes, Leonard Duncan, John H. Kimbrough, Cecilia G. Carvalhaes, Mariana Castanheira

Summary: A total of 35,360 Enterobacterales isolates were collected from US medical centers from 2018 to 2022. Among them, 7.4% were identified as multidrug-resistant (MDR). Susceptibility testing and whole genome sequencing were conducted to determine the resistance profiles and carbapenemase genes. The most active β-lactamase inhibitor combination against carbapenem-resistant Enterobacterales (CRE) isolates was ceftazidime-avibactam, followed by meropenem-vaborbactam and imipenem-relebactam. Ceftazidime-avibactam exhibited greater activity against OXA-48-type producers.

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2023)

Article Infectious Diseases

Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with urinary tract infections (2021)

Helio S. Sader, Cecilia G. Carvalhaes, Michael D. Huband, Rodrigo E. Mendes, Mariana Castanheira

Summary: We evaluated the in vitro activity of ceftibuten-avibactam against Enterobacterales causing urinary tract infection (UTI). The results showed that ceftibuten-avibactam exhibited high activity against a large collection of multidrug-resistant Enterobacterales isolated from patients with UTI, making it a valuable option for oral treatment of UTI caused by multidrug-resistant Enterobacterales.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2023)

Article Infectious Diseases

Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019-21)

Helio S. Sader, Mariana Castanheira, John H. Kimbrough, Valerie Kantro, Rodrigo E. Mendes

Summary: This study evaluated the in vitro activity of aztreonam/avibactam and comparators against carbapenem-resistant Enterobacterales. The results showed that aztreonam/avibactam exhibited high inhibitory activity against most isolates, including those resistant to ceftazidime/avibactam. Additionally, aztreonam/avibactam retained activity against isolates producing MBL and/or OXA-48-like enzymes, supporting its development as a treatment for infections caused by carbapenem-resistant Enterobacterales, including MBL producers.

JAC-ANTIMICROBIAL RESISTANCE (2023)

Article Oncology

Oritavancin in vitro activity against Gram-positive organisms from European medical centers: a 10-year longitudinal overview from the SENTRY Antimicrobial Surveillance Program (2010-2019)

M. A. Pfaller, R. E. Mendes, H. S. Sader, M. Castanheira, C. G. Carvalhaes

Summary: Oritavancin demonstrated potent activity against clinically relevant Gram-positive pathogens in European hospitals, with minimal differences in minimum inhibitory concentration (MIC) values and varying resistance phenotypes between Eastern and Western Europe.

JOURNAL OF CHEMOTHERAPY (2023)

Article Infectious Diseases

Five-year analysis of the in vitro activity of tedizolid against a worldwide collection of indicated species causing clinical infections: results from the Surveillance of Tedizolid Activity and Resistance (STAR) programme

Cecilia G. Carvalhaes, Helio S. Sader, Jennifer M. Streit, Rodrigo E. Mendes

Summary: The study evaluated the activity and resistance of tedizolid against different bacteria. The results showed that tedizolid exhibited good antimicrobial activity against Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, Streptococcus agalactiae, and Streptococcus anginosus group, without any resistance trends.

JAC-ANTIMICROBIAL RESISTANCE (2022)

Article Infectious Diseases

Prevalence of carbapenemase genes among carbapenem-nonsusceptible Enterobacterales collected in US hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agents

Mariana Castanheira, Lalitagauri M. Deshpande, Rodrigo E. Mendes, Timothy B. Doyle, Helio S. Sader

Summary: The study found that Klebsiella pneumoniae serine carbapenemase (KPC) production was the most common resistance mechanism among carbapenem-nonsusceptible Enterobacterales (CNSE) clinical isolates collected in US hospitals during a 5-year period. Ceftazidime/avibactam showed high activity against all carbapenemase groups except for metallo-beta-lactamase (MBL)-producing isolates.

JAC-ANTIMICROBIAL RESISTANCE (2022)

No Data Available